# Cue Biopharma Inc (CUE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CUE
## Company Profile
- Ticker: CUE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology, Immunology
## Stock Data
- Close: 26.65 USD
- Market cap: 115787962.62 USD
- Last updated: 2026-08-05
## Business Overview
### Precision Immune Engineering Company
Cue Biopharma develops immune-disease therapies with the potential to produce functional cures. Its pipeline combines externally licensed assets with programs generated through the proprietary Immuno-STAT platform.
### CUE-221 in Allergic Disease
CUE-221 is a late-stage anti-IgE asset exclusively licensed from Ascendant Health. It has a dual mechanism of action, is in Phase 2 development for allergic disease, and is planned for expansion into food allergy.
### Portfolio Sourcing Strategy
Cue combines internally engineered Immuno-STAT programs with externally sourced clinical assets. The acquisition of rights to CUE-221 adds a later-stage program while CUE-401 and other platform candidates provide internally generated pipeline depth.
### CUE-401 and Immune Tolerance
CUE-401 is a bifunctional IL-2 and TGF-β therapy designed to induce regulatory T-cell-mediated tolerance in autoimmune and inflammatory diseases. The program expands Cue’s approach from precision T-cell targeting into tolerance induction.
## Why The Stock Is Moving

As of Aug 5, 2026, CUE was little changed and closed at $26.65. No new same-company headline was identified in the current news window.

## Future Catalysts

- An IND amendment for CUE-221 in food allergy is expected to be submitted to the FDA in the second half of 2026.
- Results from Ascendant Health’s Phase 2 dose-ranging study of CUE-221 in chronic spontaneous urticaria in China are expected in the second half of 2026.
- After reviewing the Chinese Phase 2 data, Cue plans to initiate a global Phase 2b study of CUE-221 in food allergy.
- An IND for CUE-401 is expected in the second half of 2026, with a first-in-human Phase 1 study planned to begin before year-end.

## Recent News
- 2026-08-03 12:30 EST — [Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission](https://biopharmsignal.com/news/CUE/cue-biopharma-announces-appointment-of-james-m-ahlers-as-chief-financial-officer-3c179293) — Source: Cue Biopharma Inc
- 2026-07-13 12:30 EST — [Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development](https://biopharmsignal.com/news/CUE/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head--f7d28689) — Source: Cue Biopharma Inc
- 2026-07-10 01:40 EST — [Cue Biopharma Announces $50.0 Million Private Placement](https://biopharmsignal.com/news/CUE/cue-biopharma-announces-50-0-million-private-placement-de7af494) — Source: Cue Biopharma Inc
- 2026-06-02 20:05 EST — [Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution](https://biopharmsignal.com/news/CUE/cue-biopharma-announces-board-transition-and-addition-of-new-directors-with-cont-a9391e4e) — Source: Cue Biopharma Inc
- 2026-05-21 20:05 EST — [Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CUE/cue-biopharma-to-present-at-the-2026-jefferies-global-healthcare-conference-d45e24ff) — Source: Cue Biopharma Inc